Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia

Inclusion Criteria: * Japanese; * Having a symptomatic BPH diagnosed clinically by digital rectal examination and ultrasonography within the last 6 months; * Suffering for at least 6 months from lower urinary tract symptoms related to BPH. Exclusion Criteria: * Patients with mental disorders or who cannot be relied upon to understand the trial requirements and comply with the treatment regiment; * Inpatient; * Patients having participated in a clinical trial within the previous 6-month; * Patients previously treated with SL77.0499-10; * Patients whose I-PSS total score do not meet ≥ 13; * Patients whose urinary peak flow rate (PFR) do not meet 5.0-12.0mL/s for a voided volume of at least 150mL; * Patients whose residual urine are \> 200mL; The investigator will evaluate whether there are other reasons why a patient may not participate.